CDK9

Across TCGA pan-cancer cohorts, CDK9 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CDK9 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CDK9 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CDK9 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where CDK9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	0.226	1.000	.008	31	view →
CCRCC	OS	Median	IV	0.123	0.785	.009	18	view →
LUAD	DFS	Quartile	All	0.573	0.925	.002	9	view →
UCEC	DFS	Median	III,IV	0.905	0.494	.044	8	view →
GBM	OS	Median	All	0.910	0.793	.034	7	view →
PDAC	OS	Median	II,III,IV	0.761	0.894	.019	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CDK9–HNSC (OS)

Open the HNSC breakdown →